Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora (COR) CEO and Director Robert P. Mauch reported insider transactions on 10/20/2025. He exercised 3,763 stock options at $86.09 per share and sold 5,097 common shares at $326.80 per share under a Rule 10b5-1 trading plan adopted on 11/15/2024.
Following these transactions, he directly owned 37,940 common shares. The non-qualified stock option had an exercise price of $86.09 and an expiration date of 11/13/2026, with the grant previously vesting in four equal installments.
Form 144 filing: A COR insider filed notice to sell up to 31,350 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $10,251,105.07, on or about October 21, 2025 on the NYSE.
The shares comprise 2,000 acquired via restricted stock vesting on September 30, 2023 and 29,350 tied to options granted on November 13, 2019 to be exercised for cash. Over the past three months, the filer reported sales of 14,578, 14,579, and 31,350 shares for gross proceeds of $4,266,543.26, $4,227,618.42, and $9,087,157.00.
Elizabeth S. Campbell, Executive Vice President and director of Cencora, Inc. (COR), reported a sale of 1,886 shares of Cencora common stock on 10/01/2025 at a price of $313.28 per share. Following the transaction, the reporting person beneficially owned 12,824.141 shares. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan adopted on 12/20/2024. The form is signed by Ms. Campbell on 10/03/2025.
Pawan Verma, listed as EVP, Chief Data & Info Officer of Cencora, Inc. (COR), filed an initial Form 3 reporting direct beneficial ownership of 14.05 shares of the issuer's common stock. The event date listed is 10/01/2025. The filing was signed by an attorney-in-fact on 10/03/2025 and includes Exhibit 24 (Power of Attorney).
Cencora, Inc. (COR) filed a Form 144 reporting a proposed sale of 1,886 shares of common stock through Fidelity Brokerage Services LLC on or about 10/01/2025 for an aggregate market value of $590,846.08. The filing shows 193,877,881 shares outstanding, so the shares to be sold represent a de minimis portion of the company.
The securities were acquired on 09/30/2024 through restricted stock vesting from the issuer and the payment is recorded as compensation. The filer certifies they do not possess undisclosed material adverse information. No securities were reported sold by the filer in the prior three months.
Robert P. Mauch, President & CEO and Director of Cencora, Inc. (COR), reported option exercise, open-market sale and related holdings on Form 4. On 09/18/2025 he exercised 3,763 non-qualified stock options at an $86.09 exercise price, receiving 3,763 shares. The same day he sold 5,097 shares at $290 per share under a Rule 10b5-1 trading plan adopted on 11/15/2024. After these transactions he beneficially owned 44,371 shares (before the sale) and 39,274 shares (after the sale), with 3,763 shares exercisable from previously granted options. The Form was signed by an attorney-in-fact on 09/22/2025.
Steven H. Collis, Executive Chairman and Director of Cencora, Inc. (COR), reported transactions on 09/16/2025. The filing shows a sale of 31,350 common shares executed under a Rule 10b5-1 plan adopted 11/25/2024 at a weighted average price of $289.861 (tranche prices ranged from $287.372 to $292.625). The form also records an acquisition (code M) of 29,350 shares tied to a non-qualified stock option with an exercise price of $86.09, exercisable in four equal annual installments beginning 11/13/2020 and expiring 11/13/2026. Following the reported transactions, the reporting person beneficially owned 305,912.665 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Collis on 09/18/2025.
Form 144 notice for proposed sale of securities. The filing reports an intended sale of 5,097 common shares through Fidelity Brokerage Services on 09/18/2025 with an aggregate market value of $1,478,130.00. The document shows total shares outstanding of 193,877,881. Acquisition details list 1,334 shares from restricted stock vesting on 09/30/2023 recorded as compensation, and 3,763 shares from options (granted 11/13/2019) transacted 09/18/2025 for cash. The filing also discloses three prior sales by Robert P. Mauch on 06/18/2025, 07/18/2025 and 08/18/2025 of ~4,968–4,969 shares each with gross proceeds shown. Several identifying fields for the filer and issuer are not provided in the text.
Form 144 notice for Cencora, Inc. (COR) records a proposed sale of 31,350 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $9,140,092.50 and an approximate sale date of 09/16/2025. The filing breaks the lot into 2,000 shares acquired on 09/30/2023 by restricted stock vesting (compensation) and 29,350 shares tied to options granted on 11/13/2019 with a payment date of 09/16/2025 identified as cash.
The form also lists three recent insider sales by Steven Collis: 14,579 shares on 06/24/2025 for $4,266,106.98, 14,578 shares on 07/22/2025 for $4,266,543.26, and 14,579 shares on 08/19/2025 for $4,227,618.42. The notice includes the mandatory representation that the seller is not aware of undisclosed material adverse information.
Cencora, Inc. filed a Form 8-K reporting entry into material agreements. The company executed Amendment No. 2 to the Term Credit Agreement dated September 5, 2025, among the company, the lenders party thereto, and Bank of America, N.A. as administrative agent. On the same date it executed Amendment No. 2 to an Uncommitted Money Market Line Credit Agreement dated September 5, 2025, between the company and Société Générale, New York Branch as lender. The filing references the company's common stock (NYSE: COR), two series of senior notes (2.875% due 2028 and 3.625% due 2032), and certain solicitation and pre-commencement communication rules. The cover page interactive data file is embedded within the Inline XBRL document.